Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.

Literature DB >> 4083863

Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.

J M Swenson, R J Wallace, V A Silcox, C Thornsberry.

Abstract

Broth microdilution MICs were determined for 258 clinical isolates of Mycobacterium fortuitum (3 biovariants) and M. chelonae (2 subspecies) with amikacin, tobramycin, cefoxitin, doxycycline, erythromycin, and sulfamethoxazole-trimethoprim and with several new beta-lactams and aminoglycosides and ciprofloxacin. Variations in susceptibility by and within species subgroups confirm the need for susceptibility testing against clinically important strains.

Entities: Chemical Species

Mesh：

Substances：

Year: 1985 PMID： 4083863 PMCID： PMC180333 DOI： 10.1128/AAC.28.6.807

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

21 in total

1. Susceptibility of organisms in the Mycobacterium fortuitum complex to antituberculous and other antimicrobial agents.

Authors: W E Sanders; E C Hartwig; N J Schneider; R Cacciatore; H Valdez
Journal: Antimicrob Agents Chemother Date: 1977-08 Impact factor: 5.191

2. In vitro susceptibility of mycobacterium fortuitum and mycobacterium chelonei to cefoxitin.

Authors: M Casal; F Rodríguez
Journal: Tubercle Date: 1982-06

3. Activity of amikacin, erythromycin and doxycyline against Mycobacterium chelonei and Mycobacterium fortuitum.

Authors: J A Garcia-Rodriguez; F Martin-Luengo
Journal: Tubercle Date: 1978-12

4. In vitro activity of trimethoprim and sulfamethoxazole against the nontuberculous mycobacteria.

Authors: R J Wallace; K Wiss; M B Bushby; D C Hollowell
Journal: Rev Infect Dis Date: 1982 Mar-Apr

5. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei.

Authors: J R Dalovisio; G A Pankey; R J Wallace; D B Jones
Journal: Rev Infect Dis Date: 1981 Sep-Oct

6. Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei.

Authors: R J Wallace; D B Jones; K Wiss
Journal: Rev Infect Dis Date: 1981 Sep-Oct

7. Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents.

Authors: R J Wallace; J R Dalovisio; G A Pankey
Journal: Antimicrob Agents Chemother Date: 1979-11 Impact factor: 5.191

8. Antimicrobial susceptibility testing of Mycobacterium fortuitum complex.

Authors: D F Welch; M T Kelly
Journal: Antimicrob Agents Chemother Date: 1979-06 Impact factor: 5.191

9. Identification of clinically significant Mycobacterium fortuitum complex isolates.

Authors: V A Silcox; R C Good; M M Floyd
Journal: J Clin Microbiol Date: 1981-12 Impact factor: 5.948

10. In vitro susceptiiblity of Mycobacterium fortuitum and Mycobacterium chelonei to amikacin.

Authors: J R Dalovisio; G A Pankey
Journal: J Infect Dis Date: 1978-03 Impact factor: 5.226

78 in total

1. Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.

Authors: G L Woods; J S Bergmann; F G Witebsky; G A Fahle; B Boulet; M Plaunt; B A Brown; R J Wallace; A Wanger
Journal: J Clin Microbiol Date: 2000-02 Impact factor: 5.948

2. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors:
Journal: Thorax Date: 2000-03 Impact factor: 9.139

3. Sequence-based identification of Mycobacterium species using the MicroSeq 500 16S rDNA bacterial identification system.

Authors: J B Patel; D G Leonard; X Pan; J M Musser; R E Berman; I Nachamkin
Journal: J Clin Microbiol Date: 2000-01 Impact factor: 5.948

4. Clarithromycin resistance to Mycobacterium abscessus.

Authors: B A Brown-Elliott; R J Wallace
Journal: J Clin Microbiol Date: 2001-07 Impact factor: 5.948

Review 5. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors: Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal: Clin Microbiol Rev Date: 2012-07 Impact factor: 26.132

6. Successful treatment of a prosthetic joint infection due to Mycobacterium abscessus.

Authors: Andrew Petrosoniak; Paul Kim; Marc Desjardins; B Craig Lee
Journal: Can J Infect Dis Med Microbiol Date: 2009 Impact factor: 2.471

7. Mycobacterium fortuitum infections associated with laparoscopic gastric banding.

Authors: Erin C Callen; Tiffany L Kessler
Journal: Obes Surg Date: 2011-03 Impact factor: 4.129

8. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.

Authors: Richard J Wallace; Barbara A Brown-Elliott; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal: Antimicrob Agents Chemother Date: 2002-10 Impact factor: 5.191

9. Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism.

Authors: R J Wallace; V A Silcox; M Tsukamura; B A Brown; J O Kilburn; W R Butler; G Onyi
Journal: J Clin Microbiol Date: 1993-12 Impact factor: 5.948

10. Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria.

Authors: B A Brown; R J Wallace; G Onyi
Journal: Antimicrob Agents Chemother Date: 1996-04 Impact factor: 5.191